The Urinary Tract Infection Therapeutic Market is estimated to be valued at USD 9.39 billion in 2024 and with CAGR of 3% over the forecast period 2024-2031. The prevalence of urinary tract infections is increasing globally owing to factors such as lifestyle changes, increasing habits of antimicrobial drug usage and the growing geriatric population which is more vulnerable to UTIs. Furthermore, new product launches and approvals will aid market growth.
Market Dynamics:
The rising prevalence of urinary tract infections (UTIs) across the globe is a key driver boosting growth of the UTI therapeutic market. UTIs are highly common, with around 150 million cases occurring worldwide each year. The high recurrence rate of UTIs in women who have already had one infection further increases the patient pool needing treatment. The growing geriatric population is another factor augmenting the UTI prevalence, since UTIs are more common among older adults. With lifestyle changes, increasing lifestyle diseases, and deteriorating hygiene standards in developing nations, the incidence of UTIs is rising rapidly. This growing patient population drives significant demand for antibiotics and other drugs used for UTI treatment.
Rising Prevalence of Urinary Tract Infections
One of the key drivers for the Urinary Tract Infection Therapeutic Market is the rising prevalence of chronic diseases globally. Chronic diseases such as cancer, diabetes, cardiovascular diseases etc. require prolonged medical treatment which often involves intravenous administration of drugs and fluids. According to the WHO, chronic diseases accounted for approximately 60% of all deaths globally in 2018. The number of cancer cases alone is expected to rise from 14 million new cases in 2012 to 22 million by 2030. This increasing chronic disease burden will drive greater demand for intravenous therapy and intravenous solutions which are used for hydration, administration of nutrients, drugs and other fluids intravenously.
Strong Pipeline of Novel Drugs
A robust pipeline of novel drugs under development is another major market driver. Several pharmaceutical companies are investing heavily in R&D to develop more efficacious and innovative drugs to treat antibiotic-resistant UTIs. There is a growing emphasis on developing narrow-spectrum antibiotics targeted at specific bacterial strains causing UTIs. Companies are also developing non-antibiotic drugs such as vaccines, bacteriophages, and probiotics, which have lesser potential for inducing antibiotic resistance. Another ongoing research area is the development of new drug delivery systems such as intravesical formulations and nanocarriers to enhance drug penetration and achieve higher localized concentrations for improved efficacy. The successful approval and launch of these novel products in the coming years will significantly expand treatment choices and drive revenue growth of the UTI therapeutic market.
Antibiotic Resistance
The rapid global emergence and spread of antibiotic-resistant bacterial strains is a key challenge limiting the growth potential of the UTI therapeutic market. Overprescription and misuse of antibiotics have led to the development of resistance in common uropathogens like E. coli and K. pneumoniae against widely used drugs like fluoroquinolones. Multiple drug resistance is increasingly being reported from various countries. Treating resistant infections requires longer and more expensive therapy using last-resort antibiotics. This negatively impacts treatment outcomes and increases healthcare costs. It also reduces the number of effective treatment options available to physicians. The antibiotic resistance crisis has prompted regulatory crackdowns on antibiotic overuse. It has also encouraged the shift towards developing novel non-antibiotic therapies. However, resistance continues to be a major long-term restraint for the market.
Poor Diagnosis in Developing Nations
Underdeveloped diagnostic infrastructure in low and middle-income countries forms another key restraint for the UTI therapeutic market. In many developing nations, UTIs are often misdiagnosed or diagnosed late due to lack of access to laboratory tests and imaging facilities. This results in over-the-counter or inappropriate self-medication with available antibiotics without confirmation of the causative organism. Such improper antibiotic use practices greatly exacerbate the problem of antibiotic resistance. It also leads to treatment failures and unnecessary health expenditures. The low awareness and financial constraints in these regions hinders adoption of advanced diagnostic tests for accurate UTI diagnosis and tailored therapy. This restrains optimal uptake of UTI drugs and impacts overall market growth potential.
Increasing Healthcare Expenditure
Rising healthcare spending worldwide is a key opportunity area for participants in the UTI therapeutic market. Continued expansion of public and private health insurance coverage is enabling more people worldwide to seek proper medical care for UTIs. This increases the total volume of UTI drugs prescribed and consumed annually. Simultaneously, growing per capita healthcare expenditures are allowing for more revenue generation from premium and novel drug offerings that command higher price points. Countries like China, India, and several nations in Southeast Asia and Latin America now have considerably higher expenditures on healthcare compared to a decade ago. Their rising disposable incomes are pushing more citizens towards both general healthcare as well as specialty services like infertility treatment, where UTIs are highly prevalent. This growing expenditure culture presents lucrative commercialization opportunities for market players.
Advances in Drug Delivery
Innovations in drug delivery systems also offer meaningful opportunities for higher revenues. Developing advanced formulations that can achieve enhanced bioavailability, controlled release and targeting to specific infection sites could help address current challenges and bolster patient compliance. Examples include pH-responsive nanoparticles for controlled vaginal delivery, stimuli-responsive hydrogels implantable in the urinary tract, and intravesical drug-eluting stents. Such formulations stand to significantly upgrade UTI treatment by maintaining effective drug levels at sites of infection for prolonged durations using fewer doses.
Link - https://www.coherentmarketinsights.com/market-insight/urinary-tract-infection-treatment-market-1178
Key Development
- On January 23, 2024, Locus Biosciences, Inc., a biotechnology company in the clinical stage, disclosed the release of USD 23.9 million in funding from Biomedical Advanced Research and Development Authority (BARDA), which operates under the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. This funding aims to further the development of Locus Biosciences, Inc.'s Clustered regularly interspaced short palindromic repeats (CRISPR)-enhanced bacteriophage therapy, LBP-EC01, specifically for addressing urinary tract infections (UTIs) induced by drug-resistant Escherichia coli.
- In April 2023, GSK plc, a multinational pharmaceutical and biotechnology corporation, announced encouraging outcomes from the pivotal phase III trials EAGLE-2 and EAGLE-3 concerning gepotidacin. Gepotidacin is an investigational oral antibiotic characterized by a pioneering mechanism of action, intended for the treatment of uncomplicated urinary tract infections (uUTI) in female adults and adolescents. These significant findings were showcased in an oral presentation at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) held in Copenhagen, Denmark.
- In August 2021, Bayer AG, a leading multinational pharmaceutical and biotechnology firm based in Germany, revealed its acquisition of Vividion Therapeutics (Vividion), a biopharmaceutical company headquartered in the U.S. Vividion Therapeutics (Vividion) specializes in employing innovative discovery technologies to identify high-value targets traditionally considered difficult to drug, with the aim of developing precision therapeutics.
- In October 2020, Bayer AG, a prominent Germany-based multinational pharmaceutical and biotechnology corporation, completed the acquisition of Asklepios BioPharmaceutical, Inc., a gene therapy company. Asklepios BioPharmaceutical, Inc.’s portfolio encompasses investigational candidates in pre-clinical and clinical stages, targeting various conditions such as central nervous system disorders, neuromuscular conditions, and cardiovascular and metabolic diseases.
Key Players: Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others.
